CardioSignal by Precordior

CardioSignal by Precordior is a health technology startup based in Turku, Finland and Palo Alto, CA, United States, established in 2016. The company is dedicated to developing innovative solutions for early detection of heart diseases through its disruptive mobile application-based technology. Its flagship product, the CardioSignal mobile application, has obtained a CE mark as a class IIa medical device for detecting atrial fibrillation and is accessible in over 10 countries. As part of Precordior, originally an academic spinoff, CardioSignal leverages patented motion sensor technology built on a decade of research and algorithm development. The company aims to create a digital cardiac biomarker for various major heart diseases, envisioning a significant impact on Biotechnology, Health Care, Manufacturing, Medical Devices, Mobile, Autonomous, and Sensor Tech industries. With the recent non-equity assistance investment from MedTech Innovator on 29 May 2024, CardioSignal continues its mission to support healthcare in combatting the pervasive issue of heart disease, which has been identified as the leading cause of death globally. The company's focus on early identification and treatment of heart disease, particularly atrial fibrillation, aligns with the critical need to mitigate the escalating burden of strokes and heart attacks, thereby enhancing outcomes for individuals and society. This initiative addresses an urgent health and economic concern described as an epidemic by researchers and physicians worldwide.